Atherogenic Index of Plasma in Non-Alcoholic Fatty Liver Disease: Systematic Review and Meta-Analysis

• Published in: Biomedicines 2022-08, Vol.10 (9), p.2101
• Main Authors: Ismaiel, Abdulrahman, Ciobanu, Oana Sabina, Ismaiel, Mohamed, Leucuta, Daniel-Corneliu, Popa, Stefan-Lucian, David, Liliana, Ensar, Dilara, Al Srouji, Nahlah, Dumitrascu, Dan L
• Format: Article
• Language: English
• Subjects: Accuracy; Arteriosclerosis; Biomarkers; Biopsy; Cardiovascular disease; Confidence intervals; Diagnosis; Fatty liver; Handbooks; hepatic steatosis; Liver diseases; liver fibrosis; Meta-analysis; metabolic-dysfunction-associated fatty liver disease (MAFLD); Metabolism; non-alcoholic fatty liver disease (NAFLD); Ovaries; Pathogenesis; Physiological aspects; Polycystic ovary syndrome; Quality control; scores; Systematic Review; Ultrasonic imaging
• ISSN: 2227-9059; 2227-9059
• DOI: 10.3390/biomedicines10092101

(1) Background: Approximately a billion people worldwide are affected by NAFLD, which places a high clinical burden and financial cost on society. Liver biopsy is the gold standard for diagnosing NAFLD, but its invasivity limits the early diagnosis of NAFLD. Hence, it is important to look for alternate techniques in detecting and diagnosing NAFLD. NAFLD is associated with atherosclerosis. The purpose of this study was to assess the effectiveness of the atherogenic index of plasma (AIP) as a non-invasive modality for predicting NAFLD. (2) Methods: A search using electronic databases PubMed, EMBASE, and Scopus was carried out to find observational studies, looking at research that had been published up until the date of 11 May 2022. The included studies' quality, risk of bias, and internal validity were evaluated using the QUADAS-2 quality assessment tool. The key summary outcomes were the mean difference (MD) and area under the curve (AUC). (3) Results: A total of eight studies (81,178 participants) were included in our review, while 17% of the included participants had NAFLD. A sex distribution of 57.8% men and 42.2% women was observed. The AIP between NAFLD and the controls was not significant (MD 0.212 [95% CI 0.231-0.655]). A significant MD in AIP between the males and females with NAFLD was observed (MD 0.246 [95% CI 0.098-0.395]). The AIP predicted NAFLD with an AUC of 0.764 as well as in males (AUC 0.761) and females (AUC 0.733). (4) Conclusions: There was a substantial MD in the AIP between both sexes, but there was no significant difference in the AIP values between patients with NAFLD and the controls. The AIP is a reliable biomarker for the diagnosis of NAFLD since its ability to predict the development of NAFLD was comparable to that of the other biomarkers.